Equity grants to director-linked fund at Silexion Therapeutics (SLXN) disclosed

Rhea-AI Filing Summary

Noy Shlomo reported acquisition or exercise transactions in this Form 4 filing.

Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund (GIBF), an entity associated with director Noy Shlomo, was granted equity awards in connection with director services provided by GIBF’s CEO and Managing Partner, Avner Lushi. GIBF received fully vested restricted share units that were immediately settled into 9,091 ordinary shares, at a price of $0.00 per share. GIBF was also granted 10,685 stock options to purchase ordinary shares, with these options vesting in full on the one‑year anniversary of the board’s approval date and expiring on the ten‑year anniversary of that approval. The filing notes that Shlomo has shared voting and investment authority through his role as Chief Medical Officer of GIBF and disclaims beneficial ownership beyond any indirect pecuniary interest, and one line item is included only to show existing holdings with no new transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Noy Shlomo

(Last) (First) (Middle)

6 JACOB AFTER STREET

(Street)

TEL AVIV L3 6936206

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/20/2026		A(1)		9,091	A	$0	25,399	I	By Guangzhou Sino-Israel Biotech Fund(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	$1.65	02/20/2026		A(3)		10,685		02/12/2027(4)	02/12/2036(4)	Ordinary Shares	10,685	$0	10,685	I	By Guangzhou Sino-Israel Biotech Fund(2)
Stock Option (right to buy ordinary shares)(5)	$18.9							02/09/2026	02/09/2035	Ordinary Shares	1,872		1,872	I	By Guangzhou Sino-Israel Biotech Fund(2)

Explanation of Responses:

1. The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer. The grant was approved by the Issuer's board of directors.

2. The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.

3. The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer, which grant was approved by the Issuer's board of directors.

4. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.

5. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

	/s/ Mirit Horenshtein Hadar, Attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Silexion Therapeutics Corp (SLXN) disclose in this Form 4?

Silexion disclosed equity awards granted to Guangzhou Sino-Israel Biotech Fund. The fund received 9,091 ordinary shares via fully vested RSUs and 10,685 stock options, all approved by the board in connection with director services provided by GIBF’s CEO, Avner Lushi.

Who actually received the Silexion Therapeutics (SLXN) shares and options reported for Noy Shlomo?

The awards were granted to Guangzhou Sino-Israel Biotech Fund, not directly to Noy Shlomo. Shlomo is Chief Medical Officer of the fund and has shared voting and investment authority but disclaims beneficial ownership beyond any indirect pecuniary interest.

What type of equity awards did Guangzhou Sino-Israel Biotech Fund receive from Silexion (SLXN)?

Guangzhou Sino-Israel Biotech Fund received fully vested restricted share units that converted into 9,091 ordinary shares and was also granted 10,685 stock options to buy ordinary shares. Both types of awards were approved by Silexion’s board for director services.

What are the vesting and expiration terms of the Silexion (SLXN) stock options granted to GIBF?

The options vest entirely on the one-year anniversary of the grant’s board approval date and expire on the ten-year anniversary of that approval. This means they become fully exercisable after one year and cannot be exercised after the ten-year mark.

Were any cash purchases or sales involved in this Silexion (SLXN) Form 4 filing?

No cash purchases or sales were reported. The transactions consist of equity grants: RSUs that became 9,091 ordinary shares at a price of $0.00 per share and 10,685 stock options awarded as compensation for director services rather than open-market trades.

Why does the Silexion (SLXN) Form 4 include a row with no transactions?

One line item is included only for informational purposes to show existing holdings. A footnote specifies that no transactions occurred for those securities, indicating the row reflects previously held options rather than new grants, purchases, or sales.